Pharmaceuticals

Lexaria Bioscience

Lexaria Bioscience released FY2025 earnings on November 27 (EST), actual revenue USD 705.92 K (forecast USD 669 K), actual EPS USD -0.6612 (forecast USD -0.6766)

Lexaria Bioscience released FY2025 Q4 earnings on November 27 EST, actual revenue USD 174 K (forecast USD 137 K), actual EPS USD -0.1377 (forecast USD -0.1566)

Lexaria Bioscience released FY2025 9 Months Earnings on July 14 (EST), actual revenue USD 531.92K, actual EPS USD -0.5242

Lexaria Bioscience released FY2025 Q3 earnings on July 14 (EST), actual revenue USD 174 K (forecast USD 137 K), actual EPS USD -0.207 (forecast USD -0.145)

Lexaria Secures Patent for Epilepsy Treatment and Nicotine Delivery

Lexaria Bioscience Corp Adds Expenses to Clinical Study

Lexaria's Oral Drug Delivery Technology Clinical Study Success

Lexaria to Attend International Biotech Conference to Promote Drug Delivery Technology

Lexaria Completes Preliminary Clinical Research on DehydraTECH Technology

Lexaria Bioscience released FY2025 Q2 earnings on April 14 (EST), actual revenue USD 174 K (forecast USD 91.33 K), actual EPS USD -0.1549 (forecast USD -0.1633)

Lexaria Bioscience released its FY2025 semi-annual earnings on April 14, 2025 (EST), with actual revenue of USD 357.92K and EPS of USD -0.3174

Lexaria Bioscience Initiates Human Study of Oral Drug Administration

Lexaria Bioscience Corp. Launches Dehydrogenation Technology Study with Market Value of $32.65 Million

Lexaria Bioscience Corp. Achieves Significant Progress in GLP-1 Drug Delivery in 2024

Lexaria Bioscience released FY2025 Q1 earnings on January 10 (EST), actual revenue 183.92 K USD (forecast 100 K USD), actual EPS -0.1622 USD (forecast -0.12 USD)

Lexaria Bioscience released FY2024 Annual Earnings on November 26 (EST), Actual Revenue 464.28K USD (Forecast 403.67K USD), Actual EPS -0.4679 (Forecast -0.44)

Lexaria Bioscience released FY2024 Q4 earnings on November 26 (EST), actual revenue 84K USD (forecast 100K USD), actual EPS -0.139 USD (forecast -0.1133 USD)

Lexaria Bioscience: H.c. Wainwright initiates coverage with a buy rating

Starfighters Space

Haoxin

Sidus Space

Mega Fortune

Jyong Biotech

Hycroft Mining

Velo3D

Tradr 2X Long QBTS Daily ETF

Creative Media & Community Trust

Tradr 2X Long FLY Daily ETF

Eli Lilly

Roche

ROCHE HOLDINGS AG

Astrazeneca

NOVARTIS AG

Novo Nordisk AS

Chugai Pharmaceutical

UCB S.A.

Daiichi Sankyo

Otsuka Pharmaceutical

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap